Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Cingulate Inc.

NASDAQ: CING · Life Sciences · 4 alerts · CIK 1862150

Share price
$3.75Close, Nov 16
Market cap
$56.1M
Shares outstanding
14.96MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cingulate Inc. filings on SEC EDGAR ↗

5:23 PM ET 10-Q
Financial Results

Cingulate Q3 2026 Results: Net Loss of $7.73M, Loss Widens

Cingulate Inc. reported a net loss of $22.9 million for the nine months ended September 30, 2026, as it continues to develop its ADHD drug candidates CTx-1301 and CTx-1302. Despite receiving a Complete Response Letter from the FDA for CTx-1301 in June 2026, the company strengthened its liquidity position to $23.2 million in cash through significant financing activities, including at-the-market offerings and private placements.

Key figure
Net loss $7.73M
5:19 PM ET 8-K
Financial Results

Cingulate Financial Results

Cingulate reported Q3 2026 financial results, highlighting a cash position of $23.2 million and progress on its CTx-1301 NDA resubmission. The company has substantially completed manufacturing work to address FDA CMC requests and expects to resubmit the NDA between December 2026 and January 2027. Additionally, the company added Maxim Group LLC as a sales agent to its existing $100 million ATM equity offering program.

Term
Q3 2026

“With the manufacturing work substantially complete, we are now finalizing the data and documentation needed to resubmit the NDA for CTx-1301, and we expect to do so by January 2027, potentially sooner.”

Shane J. Schaffer, Chairman and CEO

“Importantly, the FDA’s Complete Response Letter did not raise any concerns about the clinical safety or efficacy of CTx-1301. We thank our shareholders for their patience and continued support as we work to bring this treatment to patients with ADHD.”

Shane J. Schaffer, Chairman and CEO

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.